The Bowel Research Collaborative Data Tracking System Implementation Study

NCT00728975

Last updated date
Study Location
BC Cancer Agency
Vancouver, British Columbia, V5Z 4E6, Canada
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Constipation
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
0 +
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients receiving palliative care

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- None

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

ConstipationThe Bowel Research Collaborative Data Tracking System Implementation Study
NCT00728975
  1. Vancouver, British Columbia
ALL GENDERS
0+
years
MULTIPLE SITES
ConstipationStudy Evaluating Long-Term Safety of MOA-728 in Participants With Opioid-Induced Constipation
NCT00804141
  1. Birmingham, Alabama
  2. Chandler, Arizona
  3. Mesa, Arizona
  4. Mesa, Arizona
  5. Phoenix, Arizona
  6. Phoenix, Arizona
  7. Tempe, Arizona
  8. Tucson, Arizona
  9. Tucson, Arizona
  10. Hot Springs, Arkansas
  11. Garden Grove, California
  12. Laguna Hills, California
  13. Los Gatos, California
  14. Newport Beach, California
  15. Newport Beach, California
  16. Colorado Springs, Colorado
  17. Boca Raton, Florida
  18. Brandon, Florida
  19. Chiefland, Florida
  20. Clearwater, Florida
  21. Daytona Beach, Florida
  22. Fort Myers, Florida
  23. Gainesville, Florida
  24. Jacksonville, Florida
  25. Jacksonville, Florida
  26. Jupiter, Florida
  27. Miami, Florida
  28. Miami, Florida
  29. Ocala, Florida
  30. Ocala, Florida
  31. Ocala, Florida
  32. Orlando, Florida
  33. Ormond Beach, Florida
  34. Port Orange, Florida
  35. Sarasota, Florida
  36. Sarasota, Florida
  37. Tampa, Florida
  38. Tampa, Florida
  39. Vero Beach, Florida
  40. Winter Park, Florida
  41. Chicago, Illinois
  42. Rockford, Illinois
  43. Avon, Indiana
  44. Evansville, Indiana
  45. Indianapolis, Indiana
  46. Indianapolis, Indiana
  47. West Des Moines, Iowa
  48. Madisonville, Kentucky
  49. Hagerstown, Maryland
  50. Hollywood, Maryland
  51. Boston, Massachusetts
  52. Brockton, Massachusetts
  53. Watertown, Massachusetts
  54. Bingham Farms, Michigan
  55. Chesterfield, Michigan
  56. Kalamazoo, Michigan
  57. Traverse City, Michigan
  58. Edina, Minnesota
  59. Biloxi, Mississippi
  60. Jackson, Mississippi
  61. Springfield, Missouri
  62. Omaha, Nebraska
  63. Henderson, Nevada
  64. Las Vegas, Nevada
  65. Las Vegas, Nevada
  66. Las Vegas, Nevada
  67. Elizabeth, New Jersey
  68. Albuquerque, New Mexico
  69. Great Neck, New York
  70. New York, New York
  71. Charlotte, North Carolina
  72. Raleigh, North Carolina
  73. Fargo, North Dakota
  74. Centerville, Ohio
  75. Dayton, Ohio
  76. Oklahoma City, Oklahoma
  77. Medford, Oregon
  78. Portland, Oregon
  79. Altoona, Pennsylvania
  80. Levittown, Pennsylvania
  81. Yardley, Pennsylvania
  82. Cranston, Rhode Island
  83. Huntingdon, Tennessee
  84. Austin, Texas
  85. Beaumont, Texas
  86. Dallas, Texas
  87. Dallas, Texas
  88. Houston, Texas
  89. Hurst, Texas
  90. San Antonio, Texas
  91. San Antonio, Texas
  92. Salt Lake City, Utah
  93. Christiansburg, Virginia
  94. Bellevue, Washington
  95. Broadmeadow, New South Wales
  96. Edmonton, Alberta
  97. Kelowna, British Columbia
  98. Vancouver, British Columbia
  99. Winnipeg, Manitoba
  100. Mount Pearl, Newfoundland and Labrador
  101. Dartmouth, Nova Scotia
  102. Hamilton, Ontario
  103. London, Ontario
  104. Oshawa, Ontario
  105. Sarnia, Ontario
  106. Toronto, Ontario
  107. Mirabel, Quebec
  108. Sainte-Foy, Quebec
  109. Sherbrooke, Quebec
  110. St-Romuald, Quebec
  111. Trois-Rivieres, Quebec
  112. Quebec,
  113. Barranquilla, Atlantico
  114. Bogota, Cundinamarca
  115. Suwon, Kyonggi-do
  116. Seoul, Seoul/Korea
  117. Seoul,
  118. Seoul,
  119. Badalona, Barcelona/Spain
  120. Madrid, Madrid/Spain
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title The Bowel Research Collaborative Data Tracking System Implementation Study
Official Title The Bowel Research Collaborative Data Tracking System Implementation Study
Brief Summary The project's primary purpose is to establish a network of Hospice Palliative Care settings using a common and consistent method of assessing and documenting bowel functioning in order to be able to carry out future collaborative studies of constipation treatments. The secondary goal is to gather normative data on current bowel care function and outcomes of current treatments which can be used to determine sample size calculations for future controlled trials of bowel management protocols. In order to complete this goal the project requires a thorough assessment of current nursing practice in regard to bowel care.
Detailed Description

Site assessment: Each site will be assessed as to their current bowel assessment and documentation methods, and their current bowel management strategy. Clinical practice leaders (nursing and physician) will be interviewed, and as many of the nurses as can be contacted will be asked to complete a brief questionnaire about bowel care at their site, with some focus groups being held in order to allow all staff to have input.

A retrospective chart review will be carried out to include at least 30 patients to establish the current documentation standard and outcomes.

The impact of bowel care on nursing practice will be assessed.

Intervention: As a result of the assessments at all the sites and in collaboration with the site leaders, the research team will devise a common reporting and documentation system which will enable systematic collection of bowel outcomes data. It is intended that the Victoria Bowel Performance Scale will be introduced, in combination with other reporting tools specific to bowel management. The tools may vary from site to site depending on the context of care, for example an inpatient unit will have differing requirements to an outpatient clinic. However the goal is for required outcome data to be retrievable from charts from all settings in a consistent, complete and reliable way.

Evaluation: Medical and nursing staff will be surveyed in the same way as in the initial assessment (interviews, questionnaires and focus groups), to assess the performance and acceptability of the modified reporting process. A second chart review will be undertaken when at least 30 patients have passed through the service. Outcomes from the chart reviews will be communicated back to care providers in order to give them feedback as to the quality of bowel care they are providing. Any further modifications to the data tracking system will be made so that by the end of the project the system is acceptable to all sites and functioning effectively, allowing the network of collaborating sites to proceed to the next step: clinical trials of different bowel care treatments.

Demographic data recorded will be that required to determine comparability of cohorts with respect to risk for constipation and will include the following variables.

  • Age
  • Gender
  • Palliative Performance Status (PPSv2) on admission
  • Diagnosis (if cancer, which tumour type)
  • Major comorbid diagnoses
  • Reason for admission
  • Presence or absence of abdominal cancer
  • Presence or absence of ascites
  • Radiotherapy during admission (if yes, to abdomen or not)
  • Medications taken during admission
  • Duration of admission
  • Number of days on bowel protocol
  • Discharge or death

The primary outcome measures for bowel function for each patient will be the proportion of days with at least one bowel movement a day, and the proportion of patients with a bowel movement at least 40 % and at least 50% of days. The secondary outcome variables of the study will be use of enemas, suppositories or lactulose, and reported cramping and/or diarrhoea. Diarrhoea will be defined as either passage of watery stool at least once a day, or more than 3 bowel movements a day. These were the same outcome variables used in the docusate study. Sites will be grouped according to type of setting (hospice, PCU, home etc). Sites with very similar patients will be combined for statistical analysis (for example the two Vancouver residential hospices to which patients are referred through a common process and assigned to according to bed availability).

Acceptability of the BPS will be assessed through a combination of questionnaires and focus groups with staff at sites which elect to pilot it after reviewing the results of the initial assessment. Their responses will be analysed using qualitative methodology. Staff will also be asked at the end of the study whether or not they would prefer to continue to use the BPS for routine clinical assessment or to revert to their previous method.

The utility of the BPS as a suitable outcome measure for clinical trials of bowel management treatments will be explored by correlating the single item BPS score with the primary and secondary outcome variables. As scoring of the BPS is essentially a composite of multiple outcome variables, (bowel movement frequency, consistency, degree of sphincter control and associated symptoms such as cramping etc.) it is anticipated that the BPS will provide at least the same outcome information as the multiple individual variables, which are rarely fully documented. We hope that the BPS will provide more patient-centred and useful information to guide laxative treatment, as the tool is centred around the individual's "normal" bowel habit, rather than relying on arbitrarily defined norms. Data from all sites will be able to be pooled for this analysis.

Study Type Observational
Study Design Observational Model: Cohort
Time Perspective: Retrospective
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients receiving palliative care
Condition Constipation
Intervention Not Provided
Study Groups/Cohorts
  • 1
    Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Centre,
  • 2
    Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Centre for Southern Interior
  • 3
    Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Fraser Valley Centre
  • 4
    Pain and Symptom Management/Palliative Care Clinic outpatients, BC Cancer Agency, Vancouver Island Centre
  • 5
    Vancouver Coastal Cottage Hospice inpatients
  • 6
    Vancouver Coastal Richmond Palliative Care Program patients
  • 7
    Vancouver Coastal Lions Gate Palliative Care Unit inpatients
  • 8
    Providence Health St Paul's Hospital Palliative Care Unit inpatients
  • 9
    Providence Health Marion Hospice inpatients
  • 10
    Vancouver Island Health Authority Victoria Hospice inpatients
  • 11
    Fraser Health Burnaby Hospital Tertiary Palliative Care Unit inpatients
  • 12
    Fraser Health Mission Hospice inpatients
  • 13
    Fraser Health Langley Hospice inpatients
Publications * Hawley P, Barwich D, Kirk L. Implementation of the victoria bowel performance scale. J Pain Symptom Manage. 2011 Dec;42(6):946-53. doi: 10.1016/j.jpainsymman.2011.02.021. Epub 2011 May 26.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 1, 2018)
533
Original Estimated Enrollment
 (submitted: August 5, 2008)
390
Actual Study Completion Date February 2010
Actual Primary Completion Date February 2010   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Patients receiving palliative care

Exclusion Criteria:

  • None
Sex/Gender
Sexes Eligible for Study:All
Ages Child, Adult, Older Adult
Accepts Healthy Volunteers No
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Canada
Removed Location Countries  
 
Administrative Information
NCT Number NCT00728975
Other Study ID Numbers H08-01321
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Pippa Hawley, British Columbia Cancer Agency
Study Sponsor British Columbia Cancer Agency
Collaborators Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Principal Investigator:Philippa Dr Hawley, B.MedBritish Columbia Cancer Agency
PRS Account British Columbia Cancer Agency
Verification Date November 2018